FierceBiotech4h
Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
FiercePharma1d
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
Bristol Myers price target raised to $62 from $60 at Wells Fargo
Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $62 from $60 and keeps an Equal Weight rating on the shares. While ...
Bristol Adds to Cost Cutting With Outlook Missing Estimates
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...